

Ms J Gambell  
CANCER RESEARCH UK & UNIV. COLL. LONDON CANCER TRIALS CENTRE  
HAEMATOLOGY TRIALS GROUP  
90 TOTTENHAM COURT ROAD  
LONDON  
W1T 4TJ  
UNITED KINGDOM

21/06/2010

Dear Ms J Gambell

**THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031**

Our Reference:	20363/0273/001-0004
Eudract Number:	2009-012717-22
Product:	rituximab
Protocol number:	UCL/08/0167
Substantial Amendment Code Number:	Amendment 2/Protocol 2.0_PIS 2.1_Pregnant Partner PIS & CF/20may10

**NOTICE OF ACCEPTANCE OF AMENDMENT**

I am writing to inform you that the Licensing Authority accepts the proposed amendment to your clinical trial authorisation (CTA), received on 24/05/2010.

This amendment may therefore be made.

You are reminded that where it is appropriate, the Ethics Committee should also be notified of amendments.

Yours sincerely,

**Clinical Trials Unit  
MHRA**